Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwrit...
05 December 2020 - 8:01AM
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex
vivo, announced today the closing of an underwritten public
offering of 5,513,699 shares of its common stock, including the
exercise in full by the underwriters of their option to purchase an
additional 719,178 shares, at the public offering price of $36.50
per share. The gross proceeds raised in the offering, before
underwriting discounts and commissions and expenses of the
offering, were approximately $201 million.
Goldman Sachs & Co. LLC, Jefferies LLC and SVB Leerink LLC
acted as joint book-running managers for the offering.
The shares of common stock were offered by Intellia pursuant to
a shelf registration statement that was previously filed with the
U.S. Securities and Exchange Commission (SEC) and automatically
became effective upon filing. A final prospectus supplement and
accompanying prospectus relating to and describing the terms of the
offering was filed with the SEC on December 2, 2020. The final
prospectus supplement and accompanying prospectus relating to the
offering may be obtained from: Goldman Sachs & Co. LLC, by mail
at 200 West Street, New York, NY 10282, Attention: Prospectus
Department, by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com; or Jefferies LLC, by mail at 520
Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity
Syndicate Prospectus Department, by telephone at (877) 547-6340, or
by email at Prospectus_Department@Jefferies.com; or SVB Leerink
LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110,
Attention: Syndicate Department, by telephone at (800) 808-7525,
ext. 6132, or by email at syndicate@svbleerink.com; or by accessing
the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding Intellia’s anticipated public offering. The words “may,”
“will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Intellia’s most recent annual report on Form 10-K and quarterly
report on Form 10-Q filed with the SEC, as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the SEC, including those contained or
incorporated by reference in the final prospectus supplement and
accompanying prospectus related to the public offering filed with
the SEC. Any forward-looking statements contained in this press
release represent Intellia’s views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Intellia explicitly disclaims any obligation to
update any forward-looking statements, except as required by
law.
Intellia
Contacts:
Investors:Lina LiAssociate DirectorInvestor
Relations+1 857-706-1612lina.li@intelliatx.com
Media:Jennifer Mound SmoterSenior Vice
PresidentExternal Affairs & Communications+1
857-706-1071jenn.smoter@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Jul 2023 to Jul 2024